Nevirapine resistance after single dose prophylaxis.

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor effective against HIV-1.
• The HIVNET 012 trial demonstrated NVP's efficacy in preventing HIV-1 mother-to-child transmission (MTCT) in resource-poor settings.
• The NVP regimen involves a single dose for mothers during labor and for infants within 72 hours of birth.

Purpose of the Study:

• To review the emergence and fading of Nevirapine-resistant HIV-1 in women and infants receiving single-dose NVP prophylaxis.
• To discuss the potential clinical significance of Nevirapine resistance in the context of MTCT prevention.

Main Methods:

• Review of studies examining Nevirapine resistance following single-dose NVP prophylaxis.
• Analysis of factors influencing NVP resistance, including baseline viral load, CD4 cell counts, and HIV-1 subtype.
• Assessment of the temporal dynamics of NVP-resistant HIV-1 detection in women and infants.

Main Results:

• Single-dose Nevirapine prophylaxis can lead to the emergence of NVP-resistant HIV-1.
• Emergence of resistance is more prevalent in women with high baseline viral loads and low CD4 cell counts.
• NVP-resistant HIV-1 strains typically decrease in prevalence over time in both mothers and infants.

Conclusions:

• While effective for MTCT prevention, single-dose Nevirapine use can select for drug-resistant HIV-1.
• The clinical relevance of transient NVP resistance in this setting requires careful consideration.
• Understanding resistance patterns is crucial for optimizing HIV treatment and prevention strategies in resource-limited areas.